- Home
- YSXT vs LITS Comparison
YSXT vs LITS Comparison
Compare YSXT & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | LITS |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 25.7M |
| IPO Year | 2023 | 2003 |
Fundamental Metrics
Financial Performance| Metric | YSXT | LITS |
|---|---|---|
| Price | $1.27 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.0K | ★ 308.3K |
| Earning Date | 02-03-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.69 |
| 52 Week High | $5.01 | $2.97 |
Technical Indicators
Market Signals| Indicator | YSXT | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 57.97 |
| Support Level | $0.98 | $0.97 |
| Resistance Level | $1.31 | $1.23 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 54.02 | 56.83 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.